MicroRNA-503 suppresses proliferation and cell-cycle progression of endometrioid endometrial cancer by negatively regulating cyclin D1

FEBS Journal

Volumn 280, Issue 16, 2013, Pages 3768-3779

  Xu, Yan Ying ^a   Wu, Hui Juan ^b   Ma, Hong Da ^a   Xu, Li Ping ^a   Huo, Yan ^a   Yin, Li Rong ^a  

^a SECOND HOSPITAL OF TIANJIN MEDICAL UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

cyclin D1; endometrioid endometrial cancer; microRNA; miR 503; target gene

Indexed keywords

CYCLIN D1; MICRORNA; MICRORNA 503; UNCLASSIFIED DRUG; CCND1 PROTEIN, HUMAN; MIRN503 MICRORNA, HUMAN; RECOMBINANT PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER INHIBITION; CANCER SURVIVAL; CELL CYCLE ARREST; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; CYCLIN D1 GENE; ENDOMETRIOID ENDOMETRIAL CANCER; ENDOMETRIUM CANCER; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MITOSIS INHIBITION; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; SURVIVAL TIME; 3' UNTRANSLATED REGION; AGED; ANIMAL; CELL CYCLE; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG SCREENING; ENDOMETRIOID CARCINOMA; ENDOMETRIUM; ENDOMETRIUM HYPERPLASIA; ENDOMETRIUM TUMOR; GENE EXPRESSION REGULATION; GENE TRANSFER; GENETICS; METABOLISM; MIDDLE AGED; MIR-503; NUDE MOUSE; PATHOLOGY; REPORTER GENE; TARGET GENE; TUMOR CELL LINE;

CYCLIN D1; ENDOMETRIOID ENDOMETRIAL CANCER; MICRORNA; MIR-503; TARGET GENE;

3' UNTRANSLATED REGIONS; AGED; ANIMALS; CARCINOMA, ENDOMETRIOID; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN D1; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOMETRIUM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE TRANSFER TECHNIQUES; GENES, REPORTER; HUMANS; MICE; MICE, NUDE; MICRORNAS; MIDDLE AGED; RECOMBINANT PROTEINS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84885914670     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.12365     Document Type: Article

References (31)

1. Jemal A, Siegel R, Ward E, Murray T, Xu J, &, Thun MJ, (2007) Cancer statistics, 2007. CA Cancer J Clin 57, 43-66.
2. Murayama-Hosokawa S, Oda K, Nakagawa S, Ishikawa S, Yamamoto S, Shoji K, Ikeda Y, Uehara Y, Fukayama M, McCormick F, et al,. (2010) Genome-wide single-nucleotide polymorphism arrays in endometrial carcinomas associate extensive chromosomal instability with poor prognosis and unveil frequent chromosomal imbalances involved in the PI3-kinase pathway. Oncogene 29, 1897-1908.
3. Bartel DP, (2009) MicroRNAs: target recognition and regulatory functions. Cell 136, 215-233.
4. Farazi TA, Spitzer JI, Morozov P, &, Tuschl T, (2011) miRNAs in human cancer. J Pathol 223, 102-115.
5. Lujambio A, &, Lowe SW, (2012) The microcosmos of cancer. Nature 482, 347-355.
6. Devor EJ, Hovey AM, Goodheart MJ, Ramachandran S, &, Leslie KK, (2011) microRNA expression profiling of endometrial endometrioid adenocarcinomas and serous adenocarcinomas reveals profiles containing shared, unique and differentiating groups of microRNAs. Oncol Rep 26, 995-1002.
7. Myatt SS, Wang J, Monteiro LJ, Christian M, Ho KK, Fusi L, Dina RE, Brosens JJ, Ghaem-Maghami S, &, Lam EW, (2010) Definition of microRNAs that repress expression of the tumor suppressor gene FOXO1 in endometrial cancer. Cancer Res 70, 367-377.
8. Jiang F, Liu T, He Y, Yan Q, Chen X, Wang H, &, Wan X, (2011) MiR-125b promotes proliferation and migration of type II endometrial carcinoma cells through targeting TP53INP1 tumor suppressor in vitro and in vivo. BMC Cancer 11, 425.
9. Dong P, Kaneuchi M, Watari H, Hamada J, Sudo S, Ju J, &, Sakuragi N, (2011) MicroRNA-194 inhibits epithelial to mesenchymal transition of endometrial cancer cells by targeting oncogene BMI-1. Mol Cancer 10, 99.
10. Tsuruta T, Kozaki K, Uesugi A, Furuta M, Hirasawa A, Imoto I, Susumu N, Aoki D, &, Inazawa J, (2011) miR-152 is a tumor suppressor microRNA that is silenced by DNA hypermethylation in endometrial cancer. Cancer Res 71, 6450-6462.
11. Huang YW, Liu JC, Deatherage DE, Luo J, Mutch DG, Goodfellow PJ, Miller DS, &, Huang TH, (2009) Epigenetic repression of microRNA-129-2 leads to overexpression of SOX4 oncogene in endometrial cancer. Cancer Res 69, 9038-9046.
12. Torres A, Torres K, Paszkowski T, Jodlowska-Jedrych B, Radomanski T, Ksiazek A, &, Maciejewski R, (2011) Major regulators of microRNAs biogenesis Dicer and Drosha are down-regulated in endometrial cancer. Tumour Biol 32, 769-776.
13. Amant F, Moerman P, Neven P, Timmerman D, Van Limbergen E, &, Vergote I, (2005) Endometrial cancer. Lancet 366, 491-505.
14. Rissland OS, Hong SJ, &, Bartel DP, (2011) MicroRNA destabilization enables dynamic regulation of the miR-16 family in response to cell-cycle changes. Mol Cell 43, 993-1004.
15. Griffiths-Jones S, Saini HK, van Dongen S, &, Enright AJ, (2008) miRBase: tools for microRNA genomics. Nucleic Acids Res 36, D154-D158.
16. Caporali A, &, Emanueli C, (2011) MicroRNA-503 and the extended microRNA-16 family in angiogenesis. Trends Cardiovasc Med 21, 162-166.
17. Corbetta S, Vaira V, Guarnieri V, Scillitani A, Eller-Vainicher C, Ferrero S, Vicentini L, Chiodini I, Bisceglia M, Beck-Peccoz P, et al,. (2010) Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue. Endocr Relat Cancer 17, 135-146.
18. Tombol Z, Szabo PM, Molnar V, Wiener Z, Tolgyesi G, Horanyi J, Riesz P, Reismann P, Patocs A, Liko I, et al,. (2009) Integrative molecular bioinformatics study of human adrenocortical tumors: microRNA, tissue-specific target prediction, and pathway analysis. Endocr Relat Cancer 16, 895-906.
19. Forrest AR, Kanamori-Katayama M, Tomaru Y, Lassmann T, Ninomiya N, Takahashi Y, de Hoon MJ, Kubosaki A, Kaiho A, Suzuki M, et al,. (2010) Induction of microRNAs, mir-155, mir-222, mir-424 and mir-503, promotes monocytic differentiation through combinatorial regulation. Leukemia 24, 460-466.
20. Sarkar S, Dey BK, &, Dutta A, (2010) MiR-322/424 and -503 are induced during muscle differentiation and promote cell cycle quiescence and differentiation by down-regulation of Cdc25A. Mol Biol Cell 21, 2138-2149.
21. Jiang Q, Feng MG, &, Mo YY, (2009) Systematic validation of predicted microRNAs for cyclin D1. BMC Cancer 9, 194.
22. Caldon CE, Sutherland RL, &, Musgrove E, (2010) Cell cycle proteins in epithelial cell differentiation: implications for breast cancer. Cell Cycle 9, 1918-1928.
23. Velasco-Velazquez MA, Li Z, Casimiro M, Loro E, Homsi N, &, Pestell RG, (2011) Examining the role of cyclin D1 in breast cancer. Future Oncol 7, 753-765.
24. Hasanali Z, Sharma K, &, Epner E, (2012) Flipping the cyclin D1 switch in mantle cell lymphoma. Best Pract Res Clin Haematol 25, 143-152.
25. Chen C, Chang YC, Lan MS, &, Breslin M, (2013) Leptin stimulates ovarian cancer cell growth and inhibits apoptosis by increasing cyclin D1 and Mcl-1 expression via the activation of the MEK/ERK1/2 and PI3K/Akt signaling pathways. Int J Oncol 42, 1113-1119.
26. Musgrove EA, Caldon CE, Barraclough J, Stone A, &, Sutherland RL, (2011) Cyclin D as a therapeutic target in cancer. Nat Rev Cancer 11, 558-572.
27. Peurala E, Koivunen P, Haapasaari KM, Bloigu R, &, Jukkola-Vuorinen A, (2013) The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer. Breast Cancer Res 15, R5.
28. Nie Y, Han BM, Liu XB, Yang JJ, Wang F, Cong XF, &, Chen X, (2011) Identification of MicroRNAs involved in hypoxia- and serum deprivation-induced apoptosis in mesenchymal stem cells. Int J Biol Sci 7, 762-768.
29. Caporali A, Meloni M, Vollenkle C, Bonci D, Sala-Newby GB, Addis R, Spinetti G, Losa S, Masson R, Baker AH, et al,. (2011) Deregulation of microRNA-503 contributes to diabetes mellitus-induced impairment of endothelial function and reparative angiogenesis after limb ischemia. Circulation 123, 282-291.
30. Chen C, Ridzon DA, Broomer AJ, Zhou Z, Lee DH, Nguyen JT, Barbisin M, Xu NL, Mahuvakar VR, Andersen MR, et al,. (2005) Real-time quantification of microRNAs by stem-loop RT-PCR. Nucleic Acids Res 33, e179.
31. Livak KJ, &, Schmittgen TD, (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2-Δ Δ C T method. Methods 25, 402-408.